Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy
The nanocap biotech firm is pivoting into digital assets with a $540 million raise to build a canton coin–based treasury, backed by DRW and Liberty City Ventures.

What to know:
- Tharimmune raised $540 million in a private placement led by DRW and Liberty City Ventures to launch a canton coin–based treasury strategy.
- The Canton Foundation and major firms including ARK Invest, Kraken, Polychain Capital, and Tradeweb joined the round.
- The move makes Tharimmune the first public company aligned with the Canton Network, as it shifts toward operating validators and building institutional blockchain infrastructure.
Nasdaq-listed Tharimmune (THAR) has raised about $540 million in a private placement led by DRW and Liberty City Ventures, as the biotech firm pivots toward a digital asset treasury (DAT) strategy centered on canton coin (CC), the company said in a press release Monday.
THAR is up roughly 30% on the announcement. The thinly-traded canton coin, the utility token powering the Canton Network, a blockchain designed for institutional finance, is lower by 4%.
The round also drew participation from a wide range of crypto-native and traditional finance players, including ARK Invest, Bitwave, Broadridge, Clear Street, Copper, Digital Asset, Kaiko, Kenetic, Kraken, Lukka, Polychain Capital, Proof Group, SBI Group, and Tradeweb Markets, among others.
The Canton Foundation, which governs the Canton Network, also joined the round, marking Tharimmune as the first publicly traded company directly supported by the Foundation.
The company expects to close the deal around Nov. 6, pending customary conditions. Proceeds will fund the acquisition of canton coin, operational costs, and a plan to run multiple validator nodes on the Canton Network to earn CC rewards.
The Canton Network, backed by major financial institutions such as Goldman Sachs, DTCC, and BNP Paribas, aims to connect traditional financial infrastructure via interoperable smart contracts. The network reportedly processes more than 500,000 daily transactions, signaling growing institutional adoption.
Tharimmune’s biotech operations will continue under its existing team, but the firm appointed Mark Wendland as CEO to lead the treasury initiative and Mark Toomey as president.
Clear Street acted as the sole placement agent and financial advisor for the offering.
Read more: Canton Network Activity Surges as Exchanges Join Validators: Copper Research
More For You
Protocol Research: GoPlus Security

알아야 할 것:
- As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
- GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
- Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
More For You
Stripe Acqui-Hires Crypto Payments Startup Valora, Venturing Further Into Stablecoins

The team behind the Celo-based app is joining Stripe, while the intellectual property is returned to cLabs.
What to know:
- The team behind Valora, a crypto payments app, is joining Stripe to advance its blockchain and stablecoin integration.
- Stripe recently acquired crypto firms Bridge and Privy, and is developing with Paradigm the Tempo blockchain for stablecoin payments.
- Valora, built on the Celo network, became a standalone company in 2021 after raising $20 million.











